Wedbush Forecasts Increased Earnings for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for Stoke Therapeutics in a research note issued on Tuesday, January 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.59). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($2.32) EPS, FY2027 earnings at ($2.53) EPS and FY2028 earnings at ($2.27) EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

STOK has been the subject of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Leerink Partners started coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $21.29.

Stoke Therapeutics Price Performance

Shares of STOK stock opened at $8.96 on Friday. The company has a market cap of $474.58 million, a P/E ratio of -4.27 and a beta of 0.95. Stoke Therapeutics has a one year low of $4.09 and a one year high of $17.58. The firm has a 50-day moving average of $11.98 and a 200-day moving average of $13.08.

Institutional Trading of Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Exome Asset Management LLC purchased a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $2,170,000. Barclays PLC boosted its holdings in shares of Stoke Therapeutics by 145.3% in the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after acquiring an additional 47,239 shares during the period. Geode Capital Management LLC raised its holdings in shares of Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Stoke Therapeutics by 338.2% in the third quarter. Jane Street Group LLC now owns 330,442 shares of the company’s stock valued at $4,061,000 after purchasing an additional 255,028 shares during the period. Finally, State Street Corp raised its position in Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after buying an additional 137,145 shares during the last quarter.

Insider Buying and Selling at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. The trade was a 8.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $178,217.10. Following the sale, the insider now directly owns 47,332 shares of the company’s stock, valued at $604,902.96. This represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock valued at $809,421 in the last three months. Company insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.